TYRA
Tyra Biosciences, Inc.Company Information
- Company Name
- Tyra Biosciences, Inc.
- CIK
- CIK0001863127
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- TYRA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TYRA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-09
- Last sale
- 2026-03-25
- Shares purchased (TTM)
- 971.89
- Shares sold (TTM)
- 365,194
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 66,656,480
- Shares outstanding
- 65,991,171
- Ownership
- 101.01%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- -23.33%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 74 | 85 | 77 | 62 | 98 | 101 | 92 | 104 | 99 | 254 | 58 | 216 | ||||||
| Marketable Securities | 280 | 299 | 179 | 213 | 198 | 218 | 249 | 256 | 274 | 128 | 145 | - | ||||||
| Prepaid Expense And Other Assets Current | 13 | 11 | 9 | 6 | 6 | 6 | 6 | 5 | 5 | 8 | 8 | 9 | ||||||
| Assets Current | 367 | 395 | 265 | 281 | 302 | 325 | 347 | 366 | 379 | 391 | 212 | 225 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | ||||||
| Operating Lease Right Of Use Asset | 5 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 9 | 10 | 9 | 13 | 11 | 10 | 7 | 6 | 5 | 5 | 5 | 5 | ||||||
| Assets | 383 | 412 | 283 | 302 | 321 | 343 | 364 | 381 | 392 | 405 | 226 | 238 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 4 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 3 | 5 | 2 | ||||||
| Operating Lease Liability Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Accrued Liabilities Current | 22 | 15 | 16 | 13 | 11 | 11 | 14 | 11 | 8 | 5 | 10 | 8 | ||||||
| Liabilities Current | 25 | 19 | 18 | 16 | 14 | 14 | 15 | 12 | 10 | 9 | 15 | 10 | ||||||
| Operating Lease Liability Noncurrent | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 30 | 24 | 23 | 21 | 19 | 20 | 20 | 18 | 16 | 15 | 22 | 16 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 810 | 798 | 630 | 617 | 609 | 602 | 594 | 586 | 578 | 573 | 369 | 364 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | -0 | -0 | 0 | - | ||||||
| Retained Earnings Accumulated Deficit | -456 | -411 | -371 | -337 | -308 | -279 | -251 | -226 | -202 | -183 | -165 | -142 | ||||||
| Stockholders Equity | 354 | 388 | 259 | 281 | 302 | 324 | 343 | 362 | 376 | 390 | 204 | 222 | ||||||
| Liabilities And Stockholders Equity | 383 | 412 | 283 | 302 | 321 | 343 | 364 | 381 | 392 | 405 | 226 | 238 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 60 | 59 | 54 | 53 | 53 | 53 | 51 | 53 | 53 | 53 | 43 | 43 | ||||||
| Shares Outstanding | 60 | 59 | 54 | 53 | 53 | 53 | 51 | 53 | 53 | 52 | 43 | 43 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTyra Biosciences, Inc. (TYRA) — SEC Financial Statements & Analysis
Tyra Biosciences, Inc. (TYRA) is a pharmaceutical preparations company, incorporated in DE. Tyra Biosciences, Inc. trades on Nasdaq as: TYRA. Tyra Biosciences, Inc. (TYRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Tyra Biosciences, Inc. carries a market cap of $2.11B, a P/E ratio of -14.19x, a P/B ratio of 5.96x, an enterprise value of $2.03B, and an EV/EBITDA multiple of -12.71x. On profitability, it posts a Return on Equity (ROE) of -45.31%, a Return on Assets (ROA) of -42.15%, and a Return on Invested Capital (ROIC) of -66.65%. Per share, it reports EPS of $-2.25, diluted EPS of $-2.25, free cash flow per share of $-1.67, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 40.38% year-over-year and EPS growth of 26.68% year-over-year. On the balance sheet, it maintains a current ratio of 14.91x, a quick ratio of 14.38x, working capital of $342.35M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.08, free cash flow of $-109.90M (TTM), and net debt of $-74.83M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.11B
- P/E TTM
- -14.19x
- EPS TTM
- $-2.25
- P/B TTM
- 5.96x
- ROE TTM
- -45.31%
- ROA TTM
- -42.15%
- Debt To Equity
- 0.08x
- Free Cash Flow TTM
- $-109.90M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Tyra Biosciences, Inc. in?
Tyra Biosciences, Inc. (TYRA) operates in the Pharmaceutical Preparations industry.
What exchange does TYRA trade on?
Tyra Biosciences, Inc. (TYRA) trades on the Nasdaq.
Where is Tyra Biosciences, Inc. incorporated?
Tyra Biosciences, Inc. is incorporated in DE.
When was Tyra Biosciences, Inc. (TYRA)'s most recent SEC filing?
Tyra Biosciences, Inc. (TYRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is TYRA's market cap?
Tyra Biosciences, Inc. (TYRA) has a market capitalization of $2.11B as of 2026-06-30.
What is TYRA's EPS (earnings per share)?
Tyra Biosciences, Inc. (TYRA)'s trailing twelve month EPS is $-2.25 as of 2026-06-30.
What is TYRA's ROE (return on equity)?
Tyra Biosciences, Inc. (TYRA)'s trailing twelve month Return on Equity (ROE) is -45.31% as of 2026-06-30.
What is TYRA's ROA (return on assets)?
Tyra Biosciences, Inc. (TYRA)'s trailing twelve month Return on Assets (ROA) is -42.15% as of 2026-06-30.
What is TYRA's ROIC (return on invested capital)?
Tyra Biosciences, Inc. (TYRA)'s trailing twelve month Return on Invested Capital (ROIC) is -66.65% as of 2026-06-30.
What is TYRA's EV/EBITDA?
Tyra Biosciences, Inc. (TYRA)'s trailing twelve month EV/EBITDA is -12.71x as of 2026-06-30.